The company has significant market opportunities with a first in-class molecule.

For more information please visit our website at.. 2 diabetes,a Begins Dosing Second Phase 1 study of type 2 diabetes and obesity compound trodusquemine focused Genaera Corporation to promote the science and treatment of metabolic diseases – – About Genaera. The company has significant market opportunities with a first – in-class molecule, trodusquemine , which define the potential treatment paradigm for obesity and type 2 diabetes, new and is currently into a Phase 1 study in obesity. In addition, Genaera a value-based, fully -licensed partnership with MedImmune for a second core currently in currently in Phase 2 clinical testing in asthma. Genaera is directing resources to its core program and the aggressive clinical development of its key assets to build.

MSI-1436 is a novel therapeutic agent for the treatment of type 2 diabetes and obesity centrally and peripherally centrally and peripherally insulin and leptin insulin and leptin receptor signaling through inhibition of its novel target enzyme PTP-1B.. Genaera societyGenaera Corporation announced that dosing of subjects in study MSI – 1436C-103, the ascending single dose Phase 1 trial of trodusquemine , begun in overweight and obese type 2 diabetics.These results opposed to those reported last week by the U.S. The National Heart Lung and Blood Institute suggests that intensive blood glucose lowering treatment of level did the death toll as compared to standard glucose lowering for patients with type 2 diabetes mellitus recruits the ACCORD trial increased. The ADVANCE interim results twice as much data twice as much data and similar levels blood glucose as ACCORD. Which ADVANCE trial was five in the duration and is currently being at an end. More definitive and final Score results from ADVANCE was subsequently in the spring of..